altoneuroscience
The VP, Commercial Planning at Alto Neuroscience leads the company's transition from a clinical-stage biotech to a launch-ready commercial organization. This role establishes the foundation for the commercial function, focusing on new product planning, commercial analytics, forecasting, and launch readiness. The position involves translating clinical, market, and competitive insights into strategic plans and infrastructure to support executive decision-making and future commercialization efforts.
Headquarters
Mountain View, California, United States
Company Size
51-200 employees
Founded
2019
Alto Neuroscience is a clinical-stage biopharmaceutical company developing precision, biology-driven medicines for neuropsychiatric conditions including major depressive disorder, bipolar depression, and schizophrenia. The company leverages over 15 years of neurobiology research and brain biology measurements to predict clinical response and identify patients most likely to benefit from its drug candidates. Alto Neuroscience aims to disrupt the trial-and-error approach to psychiatric treatment by delivering personalized and highly effective medicines that help patients get better faster.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for altoneuroscience.
Executive Director, Commercial Planning
Disc Medicine
VP, DM1 Commercial Asset Lead
Dyne Therapeutics
Executive Director, Neuroscience Global Commercial Strategy
Bristol Myers Squibb
Senior Manager, Commercial Strategy
Kingdom creates and sells Superculture® ingredients
Vice President, Marketing
Engeen
Executive Director, Marketing
Immunovant, Inc.